PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: PIPELINE ANALYSIS • Pipeline analysis PART 05: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY TYPE • Market segmentation by type • Comparison by type • Intravenous - Market size and forecast 2018-2023 • Oral - Market size and forecast 2018-2023 • Market opportunity by type PART 08: CUSTOMER LANDSCAPE PART 09: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • Americas - Market size and forecast 2018-2023 • EMEA - Market size and forecast 2018-2023 • APAC - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS • Market trends PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • ITALFARMACO • Mitsubishi Tanabe Pharma • Sanofi PART 14: APPENDIX • Research methodology • List of abbreviations Exhibit 01: Global central nervous system (CNS) disorders drugs market Exhibit 02: Segments of global central nervous system (CNS) disorders drugs market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Late-stage pipeline drugs for ALS Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Type - Market share 2018-2023 (%) Exhibit 19: Comparison by type Exhibit 20: Intravenous - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Intravenous - Year-over-year growth 2019-2023 (%) Exhibit 22: Oral - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Oral - Year-over-year growth 2019-2023 (%) Exhibit 24: Market opportunity by type Exhibit 25: Customer landscape Exhibit 26: Market share by geography 2018-2023 (%) Exhibit 27: Geographic comparison Exhibit 28: Americas - Market size and forecast 2018-2023 ($ millions) Exhibit 29: Americas - Year-over-year growth 2019-2023 (%) Exhibit 30: EMEA - Market size and forecast 2018-2023 ($ millions) Exhibit 31: EMEA - Year-over-year growth 2019-2023 (%) Exhibit 32: APAC - Market size and forecast 2018-2023 ($ millions) Exhibit 33: APAC - Year-over-year growth 2019-2023 (%) Exhibit 34: Key leading countries Exhibit 35: Market opportunity Exhibit 36: Pipeline drugs for ALS Exhibit 37: Impact of drivers and challenges Exhibit 38: Vendor landscape Exhibit 39: Landscape disruption Exhibit 40: Vendors covered Exhibit 41: Vendor classification Exhibit 42: Market positioning of vendors Exhibit 43: ITALFARMACO - Vendor overview Exhibit 44: ITALFARMACO - Organizational developments Exhibit 45: ITALFARMACO - Key offerings Exhibit 46: Mitsubishi Tanabe Pharma - Vendor overview Exhibit 47: Mitsubishi Tanabe Pharma - Business segments Exhibit 48: Mitsubishi Tanabe Pharma - Organizational developments Exhibit 49: Mitsubishi Tanabe Pharma - Geographic focus Exhibit 50: Mitsubishi Tanabe Pharma - Key offerings Exhibit 51: Sanofi - Vendor overview Exhibit 52: Sanofi - Business segments Exhibit 53: Sanofi - Organizational developments Exhibit 54: Sanofi - Geographic focus Exhibit 55: Sanofi - Segment focus Exhibit 56: Sanofi - Key offerings Exhibit 57: Validation techniques employed for market sizing  

ITALFARMACO Mitsubishi Tanabe Pharma Sanofi